Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ABCL

AbCellera Biologics Inc

6.64

Jul 13 • 10:02AM ET -0.16 (-2.35%)

Healthcare Biotechnology Canada Mid NASD

Peers: RCUS TNGX CGON KYMR NUVL RYTM BMRN INCY KRYS AXSM

| Held by: IBB CPAI SPDW IDNA GWX ONEQ BBC AVUS AVSC PDN

Scroll to Statements

Index	-
Market Cap	2.03B
Enterprise Value	1.64B
Income	-143.96M
Sales	79.21M
Book/sh	3.09
Cash/sh	1.73
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	562
IPO	Dec 11, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	25.60
P/B	2.15
P/C	3.83
P/FCF	-
EV/EBITDA	-
EV/Sales	20.68
Quick Ratio	13.89
Current Ratio	14.05
Debt/Eq	0.15
LT Debt/Eq	0.14
Option/Short	Yes / Yes

EPS (ttm)	-0.48
EPS next Y	-0.64
EPS next Q	-0.14
EPS this Y	-20.41%
EPS next Y	-9.23%
EPS next 5Y	-18.48%
EPS past 3/5Y	- -
Sales past 3/5Y	-46.31% -20.27%
EPS Y/Y TTM	15.53%
Sales Y/Y TTM	242.66%
EPS Q/Q	7.05%
Sales Q/Q	96.34%
Earnings	Aug 05 AMC
EPS/Sales Surpr.	18.32% 53.63%

Insider Own	23.04%
Insider Trans	0.00%
Inst Own	41.57%
Inst Trans	8.10%
ROA	-10.86%
ROE	-14.68%
ROIC	-13.42%
Gross Margin	61.02%
Oper. Margin	-267.61%
Profit Margin	-181.75%
SMA20	-0.20%
SMA50	15.84%
SMA200	48.98%
Trades

Shs Outstand	303.95M
Shs Float	235.02M
Short Float	20.66%
Short Ratio	6.06
Short Interest	48.56M
52W High	8.44 -21.33%
52W Low	2.74 141.89%
Volatility	10.48% 9.39%
ATR (14)	0.62
RSI (14)	51.24
Beta	1.18
Rel Volume	0.85
Avg Volume	8.02M
Volume	875,255

Perf Week	-15.63%
Perf Month	30.45%
Perf Quarter	87.57%
Perf Half Y	61.55%
Perf YTD	94.15%
Perf Year	65.58%
Perf 3Y	-10.51%
Perf 5Y	-62.76%
Perf 10Y	-
Recom	1.00
Target Price	10.50
Prev Close	6.80
Price	6.64
Change	-2.35%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-07-26	Upgrade	The Benchmark Company	Hold → Buy	$11
May-05-26	Initiated	Cantor Fitzgerald	Overweight	$7
Nov-07-25	Downgrade	Leerink Partners	Outperform → Market Perform	$4
Jul-07-25	Resumed	Leerink Partners	Outperform	$5
Aug-20-24	Downgrade	The Benchmark Company	Buy → Hold
Feb-22-24	Upgrade	The Benchmark Company	Hold → Buy	$9
Dec-05-23	Initiated	KeyBanc Capital Markets	Overweight	$6
Nov-06-23	Downgrade	The Benchmark Company	Buy → Hold
Oct-13-23	Resumed	Piper Sandler	Overweight	$20
Feb-28-23	Initiated	Cowen	Outperform
Dec-15-22	Initiated	Goldman	Buy	$30
Nov-16-22	Initiated	Truist	Buy	$29
Dec-21-21	Initiated	The Benchmark Company	Buy	$27
Nov-19-21	Initiated	Piper Sandler	Overweight	$33
Jan-05-21	Initiated	SVB Leerink	Outperform	$45
Jan-05-21	Initiated	Stifel	Buy	$59
Jan-05-21	Initiated	Credit Suisse	Outperform	$52
Jan-05-21	Initiated	BMO Capital Markets	Outperform	$48
Jan-05-21	Initiated	Berenberg	Buy	$53

Show Previous Ratings

Jul-07-26 04:05PM	AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026 (Business Wire) -7.67%
Jul-06-26 09:00AM	AbCellera Appoints Dr. Lynn Seely to its Board of Directors (Business Wire)
Jul-01-26 09:00AM	As AI Models Become Commodities, One Bio-Native AI Company Just Moved to Patent the Thing That Actually Compounds: the Data (PR Newswire)
Jun-28-26 11:56PM	Why Did SLS, MRNA, ABCL Stocks Surge To 52-Week Highs Last Week? (Stocktwits)
Jun-17-26 08:50AM	Jazz Pharmaceuticals and AbCellera Partner on Antibody Programs for Solid Tumors (InvestorsHub) +6.88%
07:00AM	Loading…
07:00AM	Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies (PR Newswire)
Jun-05-26 09:00AM	AbCellera Appoints Dr. Victor Sandor to its Board of Directors (Business Wire) -11.77%
May-12-26 03:07AM	AbCellera Biologics Inc (ABCL) Q1 2026 Earnings Call Highlights: Promising Advancements Amid ... (GuruFocus.com) -5.71%
May-11-26 04:05PM	AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635 (Business Wire)
May-07-26 04:05PM	AbCellera to Present at Upcoming Investor Conferences in May and June 2026 (Business Wire) +8.71%
Apr-20-26 09:00AM	AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call (Business Wire)
Apr-01-26 04:05PM	AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026 (Business Wire)
Mar-04-26 11:50AM	AbCellera Biologics Pivots to Pipeline as ABCL635 Phase II Hot Flash Data Nears, Exec Says (MarketBeat)
Feb-26-26 02:28PM	AbCellera Biologics (ABCL) Pivots to Clinical Stage as 2025 Revenue Hits $75M (Insider Monkey) +12.54%
Feb-25-26 08:02PM	AbCellera Biologics Inc. Q4 2025 Earnings Call Summary (Moby)
03:51AM	Loading…
03:51AM	What Sparked AbCellera Biologics To Soar Over 9% After Hours (Benzinga)
12:00AM	AbCellera Biologics Inc (ABCL) Q4 2025 Earnings Call Highlights: Navigating Growth Amidst Challenges (GuruFocus.com)
Feb-24-26 09:55PM	AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +6.27%
06:26PM	AbCellera Biologics Q4 Earnings Call Highlights (MarketBeat)
04:05PM	AbCellera Reports Full Year 2025 Business Results (Business Wire)
Feb-19-26 07:30AM	3 New Stocks SoftBank Is Betting Big on in 2026 (Barchart)
Feb-18-26 09:43AM	SoftBank Adds TwentyOne Capital, Exits Nvidia in Q4 Portfolio Shift (GuruFocus.com)
Feb-11-26 04:05PM	AbCellera to Present at Upcoming Investor Conferences in March and April 2026 (Business Wire) -6.07%
Feb-02-26 07:49PM	AbCellera Biologics Inc. (ABCL): A Bull Case Theory (Insider Monkey)
Jan-29-26 01:49PM	What Does Wall Street Think About AbCellera Biologics Inc. (ABCL)? (Insider Monkey)
Jan-22-26 04:05PM	AbCellera to Report Full Year 2025 Financial Results on February 24, 2026 (Business Wire) +8.41% -8.62%
Jan-14-26 08:07PM	AbCellera Biologics Pivots to Internal Pipeline at JPMorgan, Teases Key Milestones for 2026 (MarketBeat)
Jan-12-26 09:00AM	AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause (Business Wire)
Dec-08-25 04:05PM	AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 (Business Wire)
Dec-04-25 10:09PM	AbCellera Biologics Inc (ABCL) Down 23% Since Q3 2025 Results (Insider Monkey)
08:16AM	Loading…
Nov-25-25 08:16AM	AbCellera Biologics Inc. (ABCL) is a Buy at Stifel Nicolaus despite Wider Q3 Net Loss (Insider Monkey)
Nov-18-25 06:17AM	Why Wall Street Maintains Buy Stance on AbCellera Biologics Inc. (ABCL) Amid Business Model Evolution? (Insider Monkey)
Nov-07-25 12:12AM	AbCellera Biologics Inc (ABCL) Q3 2025 Earnings Call Highlights: Transition to Clinical-Stage ... (GuruFocus.com) -13.69%
Nov-06-25 05:45PM	AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	AbCellera Reports Q3 2025 Business Results (Business Wire)
Oct-21-25 10:47PM	AbCellera Biologics Inc. (ABCL): A Bull Case Theory (Insider Monkey)
Oct-07-25 04:05PM	AbCellera to Participate at Upcoming Investor Conferences in November and December 2025 (Business Wire) +6.93%
Sep-30-25 09:40AM	Is ABCELLERA BIOLG (ABCL) Stock Outpacing Its Medical Peers This Year? (Zacks)
Sep-29-25 04:05PM	AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025 (Business Wire)
12:00PM	AbCellera Biologics Inc. (ABCL) is a Great Momentum Stock: Should You Buy? (Zacks)
Sep-21-25 09:26AM	New CMO Appointment Strengthens AbCellera Biologics Inc. (ABCL)'s Push Into Immunology and Beyond (Insider Monkey)
Sep-20-25 02:43AM	AbCellera Biologics Inc. (ABCL) Appoints Chief Medical Officer (Insider Monkey)
Sep-15-25 08:17AM	TD Cowen Reiterates Buy Rating on ABCL After AbCellera Biologics Dosed First Participants of ABCL575 (Insider Monkey)
Sep-10-25 09:07AM	AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer (Business Wire)
Aug-28-25 05:04AM	AbCellera Biologics Inc. (ABCL) Launches First Human Trial for Menopause Therapy (Insider Monkey)
Aug-27-25 09:00AM	AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575 (Business Wire)
Aug-25-25 11:56PM	Truist Financial Reiterates a Buy Rating on AbCellera Biologics (ABCL), Sets a $10 PT (Insider Monkey)
Aug-17-25 06:10PM	AbCellera Biologics (ABCL) Advances Proprietary Pipeline with Promising Phase 1 Trial Results (Insider Monkey)
Aug-12-25 04:05PM	AbCellera to Participate at Upcoming Investor Conferences in September (Business Wire) -5.11% +7.26%
Aug-08-25 03:42AM	AbCellera Biologics Inc (ABCL) Q2 2025 Earnings Call Highlights: Revenue Surge and Clinical ... (GuruFocus.com)
Aug-07-25 06:20PM	AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
04:05PM	AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms (Business Wire)
Aug-05-25 05:55PM	Myriad Genetics (MYGN) Q2 Earnings and Revenues Surpass Estimates (Zacks) -5.50%
Jul-31-25 10:00AM	AbCellera Biologics Inc. (ABCL) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Jul-24-25 10:06AM	AbCellera Biologics Inc. (ABCL): A Bull Case Theory (Insider Monkey)
Jul-22-25 11:03AM	Leerink Partners Affirms Outperform Rating on AbCellera Biologics (ABCL) Following Pivot (Insider Monkey)
09:39AM	Strength Seen in ABCELLERA BIOLG (ABCL): Can Its 15.0% Jump Turn into More Strength? (Zacks)
Jul-07-25 04:05PM	AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025 (Business Wire) +6.05%
09:11AM	Truist Financial Lowers PT on AbCellera Biologics (ABCL) to $10 From $28, Keeps a Buy Rating (Insider Monkey)
Jun-25-25 04:09AM	AbCellera Biologics Secures Patent Validity Affirmation for Microfluidic Cell Culture Technology (Insider Monkey)
Jun-09-25 09:13AM	AbCellera Biologics Inc. (ABCL): A Bull Case Theory (Insider Monkey)
Jun-03-25 12:00PM	ABCELLERA BIOLG (ABCL) Upgraded to Buy: Here's Why (Zacks) +7.94%
Jun-02-25 06:45PM	Why AbCellera Biologics Stock Raced Nearly 6% Higher Today (Motley Fool) +5.94%
May-30-25 01:00PM	AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575 (Business Wire)
May-21-25 11:21AM	AbCellera Biologics Inc. (ABCL): Analysts See 474% Upside Potential (Insider Monkey)
May-14-25 05:00PM	AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause (Business Wire)
May-12-25 03:30PM	AbCelleras Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit (Business Wire)
May-09-25 07:30PM	AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting (Business Wire)
11:22AM	Q1 2025 Abcellera Biologics Inc Earnings Call (Thomson Reuters StreetEvents)
03:50AM	AbCellera Biologics Inc (ABCL) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com)
May-08-25 06:05PM	AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	AbCellera Reports Q1 2025 Business Results (Business Wire)
May-07-25 12:39PM	AbCellera Biologics Q1 2025 Earnings Preview (Seeking Alpha)
10:45AM	AbCellera Biologics Inc (ABCL) Q1 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Apr-29-25 03:00PM	AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025 (Business Wire)
Apr-23-25 10:14AM	Is AbCellera Biologics Inc. (ABCL) the Best Canadian Penny Stock to Invest in Now? (Insider Monkey)
Apr-16-25 11:59PM	AbCellera: Attractively Priced But A Catalyst Is Needed (Seeking Alpha)
Apr-08-25 04:05PM	AbCellera to Participate at Upcoming Investor Conferences in May and June (Business Wire) -5.85% +12.44%
Apr-03-25 04:05PM	AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025 (Business Wire) -5.86%
Mar-25-25 04:30PM	AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025 (Business Wire)
Feb-28-25 02:18PM	Q4 2024 Abcellera Biologics Inc Earnings Call (Thomson Reuters StreetEvents) -11.47%
02:43AM	AbCellera Biologics Inc (ABCL) Q4 2024 Earnings Call Highlights: Strategic Shifts Amid ... (GuruFocus.com)
Feb-27-25 10:15PM	AbCellera Biologics (ABCL) Q4 2024 Earnings Call Transcript (Motley Fool)
06:15PM	AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:05PM	AbCellera Reports Full Year 2024 Business Results (Business Wire)
Feb-26-25 07:55AM	What To Expect From AbCellera Biologics Inc (ABCL) Q4 2024 Earnings (GuruFocus.com)
Feb-11-25 04:05PM	AbCellera to Participate at Upcoming Investor Conferences in March (Business Wire) +5.08%
Jan-21-25 04:05PM	AbCellera to Report Full Year 2024 Financial Results on February 27, 2025 (Business Wire) +15.36%
Jan-17-25 07:53AM	AbCellera Biologics Inc. (ABCL): A Bull Case Theory (Insider Monkey)
Jan-15-25 10:47AM	AbbVie and Simcere Zaiming link to develop trispecific antibody (Pharmaceutical Technology) +6.86%
Jan-14-25 09:25AM	AbCellera expands collaboration with AbbVie (TipRanks) -7.67%
Jan-13-25 09:00AM	AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology (Business Wire)
Jan-07-25 09:11AM	Is AbCellera Biologics Inc. (ABCL) Among the Best Canadian Penny Stocks to Buy According to Analysts? (Insider Monkey)
Nov-21-24 04:05PM	AbCellera to Present at Upcoming Investor Conferences in December and January (Business Wire)
Nov-07-24 10:05AM	AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024 (Business Wire)
Nov-05-24 11:17AM	Q3 2024 Abcellera Biologics Inc Earnings Call (Thomson Reuters StreetEvents) -5.88%
02:11AM	AbCellera Biologics Inc (ABCL) Q3 2024 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com)
Nov-04-24 11:00PM	AbCellera Biologics (ABCL) Q3 2024 Earnings Call Transcript (Motley Fool) +5.86%
05:55PM	AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:05PM	AbCellera Reports Q3 2024 Business Results (Business Wire)

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Veronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

CEODr. Carl L.G. Hansen Ph.D.

Chief Financial OfficerMr. Andrew Booth M.B.A.

CTO & DirectorDr. Veronique Lecault Ph.D.

J.D.Mr. Tryn T. Stimart Esq.

Vice President of OperationsMr. Andrew Knowles M.Sc.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ABCL

AbCellera Biologics Inc

Upgrade your Finviz experience